Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
about
Current trends in management of hepatitis B virus reactivation in the biologic therapy eraHepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendationsLiver injury from tumor necrosis factor-α antagonists: analysis of thirty-four casesTreatment of rheumatic diseases and hepatitis B virus coinfectionClinical use of anti-TNF therapy and increased risk of infectionsDeterioration of the liver biochemistry due to reactivation of chronic hepatitis B during etanercept treatment for rheumatoid arthritisFoxp3 expression in liver correlates with the degree but not the cause of inflammation.Tumor necrosis factor blockade and the risk of viral infectionRisk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.Hepatotoxicity Associated with the Use of Anti-TNF-α AgentsIn vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity.Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Use of infliximab in particular clinical settings: management based on current evidence.Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature.Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature.Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.Safety of biologic therapy in rheumatoid arthritis.Biological therapies for inflammatory bowel disease: controversies and future options.Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.Overview of safety of non-biologic and biologic DMARDs.Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study.Hepatitis B reactivation in patients receiving targeted therapies.Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B.Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases.Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.Etanercept therapy in a hepatitis B virus (HBV)-positive psoriatic patient developing a monoclonal gammopathy of undetermined significance.Liver Illness and Psoriatic Patients.A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B
P2860
Q24634879-BF328CCE-C281-44FD-A67D-1E3071EE0FC5Q26784247-96AFAE60-6825-4D3F-9A2F-855F9AFE721CQ26864098-A717E883-5D53-446D-9083-0C918EC0CF0BQ28084305-47610664-3605-4BE2-AC9B-429B4748D5A8Q34338096-2C7ED090-DD7E-4A94-A505-5F4C5F723D4EQ34534575-1E203474-54F4-4259-825B-D521021AA5DBQ35104601-72B2BE2C-95A9-47F5-8ADE-D73BF4506E3AQ35161630-E4F8E1A3-7B30-444E-87E8-D9FE4713DFA6Q35237316-BB091479-C82B-47A5-BBD7-C3C850EB6127Q35237588-571D9DA8-734B-4AC2-96B5-94CD1F30663FQ35526652-638B9006-150F-4AD8-AE74-BACFC501908AQ36576535-69DFB964-629A-40A6-84E0-0C197C375F29Q36788495-4CA47BCF-96E4-4692-B733-68C724D68EA7Q37209089-EA5DF331-FC91-4B80-9E46-225B1B8D1883Q37223169-5CD287E0-ABFB-4920-86F3-D77B8EB6CB30Q37506064-63FED61B-4D4F-4637-A691-0FA0BBBA066BQ37655919-6F6C6C80-CB4B-4283-B3C0-C61F4A935051Q37671701-B4D4ECC6-D2FD-4EE8-BA80-BE484951D712Q37766276-F604D7AF-B870-4B99-A35E-52F79F8E799AQ37862588-D768FF27-DF9C-42FF-B0BC-55915C3A0E7BQ37944433-88D0F216-34F9-45BD-A1FD-482716515A89Q37960183-9468D9CA-9587-4BFF-8929-B5E0A5274806Q37970447-486CEDEF-3033-4326-AD82-177E251AF0C8Q38065768-E1AD4274-0F8E-4ADC-9FB8-DD3D3CE09FCBQ38810735-A75BD1EF-E3B1-49B0-AB78-AE4979A79019Q39263506-8685568C-F7CE-4E1B-A830-8FE75E00F869Q39293427-9B20CB37-2501-4BBE-BCFC-88698426E067Q43035871-8F00B92F-8B4A-412A-9C35-7FAF18BEFD44Q44464843-C3DE0D64-7428-4DE7-B3C0-A52874F27CB1Q44480405-A70ED07A-086B-4428-A0DC-049DE0E1330FQ45359495-A243DA64-5F69-46F9-8680-E68344B24506Q45361805-2A9CDF5A-8DB2-47E0-AE49-E2BD5AF4DEC2Q45364783-63E8F122-EC47-4A01-A4C3-5377B696DE11Q54254957-E2966CE8-36A1-40BE-BBDF-D78ADA4079D3Q56775958-8A4FFA7C-7A36-41CA-BE81-F7DC5CDBC2B2
P2860
Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of tumor necrosis factor-a ...... chronic hepatitis B infection.
@en
Use of tumor necrosis factor-a ...... chronic hepatitis B infection.
@nl
type
label
Use of tumor necrosis factor-a ...... chronic hepatitis B infection.
@en
Use of tumor necrosis factor-a ...... chronic hepatitis B infection.
@nl
prefLabel
Use of tumor necrosis factor-a ...... chronic hepatitis B infection.
@en
Use of tumor necrosis factor-a ...... chronic hepatitis B infection.
@nl
P1476
Use of tumor necrosis factor-a ...... chronic hepatitis B infection.
@en
P2093
Matthew B Carroll
Michael I Bond
P304
P356
10.1016/J.SEMARTHRIT.2007.10.011
P577
2008-01-25T00:00:00Z